Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Newest Biotech Joins China mRNA COVID Vaccine Race

Other Supply Deals Reached

Executive Summary

Additional Chinese coronavirus vaccine makers are now building up capacity, with Beijing-based AIM Vaccine preparing for a 400 million dose per year production capability for mRNA vaccines, while Chengdu-based Clover is to supply up to 414 million doses of its vaccines to GAVI.

You may also be interested in...



Chinese Biotechs' Foray Into mRNA Enters New Chapter With $100m Everest Deal

Everest Medicines’ deal with Canadian biotech Providence Therapeutics contains a full transfer of technology which may be appealing to Chinese regulators.

World A Step Closer To First Human Plasmid DNA Vaccine As Zydus Seeks EUA

A plasmid DNA vaccine for human use has moved a step closer to reality, with Zydus Cadila applying for an accelerated nod for its COVID-19 candidate in India. 67% efficacy reported in an interim data readout and Delta variant being the prominent strain during a Phase III trial imply better odds for approval.

How A Small Chinese Biotech Is Taking On mRNA Vaccine Giants

Originated by a Suzhou-based biotech founded two years ago and now being jointly developed with WalVax, China’s first homegrown mRNA COVID-19 vaccine is now entering the final stages of development.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144640

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel